News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Authority Backs Down in Novartis AG (NVS) Eye Drug Dispute



7/26/2012 7:04:56 AM

A regional British health authority said on Wednesday it had decided to stop using the cancer drug Avastin as a cheap alternative to eye medicine Lucentis following a legal challenge from Novartis, which sells Lucentis in Europe. Lucentis, with annualized sales for Novartis of more than $2 billion, is licensed for wet age-related macular degeneration (AMD) and recommended by Britain's health cost watchdog, the National Institute for Health and Clinical Excellence (NICE). But some hospitals in southern England have been using low doses of Roche's cancer drug Avastin as a cheaper option, even though it is not licensed for treating eye conditions.

Read at Reuters
Read at InPharm.com
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES